LBPH News and Press, Longboard Pharmaceuticals Inc. From 05/02/24

Bexicaserin (LP352) Phase 1b/2a PACIFIC Study positive topline data in participants with Developmental and Epileptic Encephalopathies (DEEs) were reported in Q1 2024 Presented late-breaking data for bexicaserin from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeti...

2024-04-30 18:00:03 ET Joel Beatty from Robert W. Baird issued a price target of $36.00 for LBPH on 2024-04-30 16:11:00. The adjusted price target was set to $36.00. At the time of the announcement, LBPH was trading at $21.3. The overall price target consensus is at $16....

2024-04-16 22:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-07 01:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

PACIFIC Study Phase 1b/2a clinical data to be featured in a podium presentation at an Emerging Science Session at the AAN Annual Meeting Data will be featured in an encore presentation at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) ...

2024-03-18 02:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-16 07:55:32 ET Summary Longboard Pharmaceuticals has seen a significant increase in its stock price following positive data from its Phase 1b/2a study of bexicaserin, a treatment for developmental and epileptic encephalopathies. The company plans to initiate a Phase 3 stud...

2024-03-12 17:04:48 ET More on Longboard Pharmaceuticals Behind The Huge Rally In Longboard Pharmaceuticals Longboard Pharma: Excellent Data In Epileptic Seizures, But We Are A Little Late Now Longboard stock up 8% as Citi initiates at buy, citing takeover potential ...

2024-03-12 16:58:39 ET More on Longboard Pharmaceuticals Behind The Huge Rally In Longboard Pharmaceuticals Longboard Pharma: Excellent Data In Epileptic Seizures, But We Are A Little Late Now Longboard stock up 8% as Citi initiates at buy, citing takeover potential ...

Bexicaserin (LP352) Phase 1b/2a PACIFIC Study positive topline data in participants with Developmental and Epileptic Encephalopathies (DEEs) was reported in January Announcing an update to the primary efficacy endpoint data previously reported in January, which show further improvement in...